Reaction

Rhinalgia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,697 reports · 75 co-occurring drugs

As of the last recalculation, Rhinalgia appears in 2,697 FAERS reports alongside 75 co-occurring drug terms. The strongest observed disproportionality signal is GENTAMICIN (PRR 31.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gentamicin	52	31.3	31.4
Cenegermin-Bkbj	45	29.2	29.3
Gentamicin Sulfate	52	25.9	26.0
Fluticasone Furoate	31	20.0	20.0
Lithium	53	16.5	16.6
Lithium Bromatum	53	16.5	16.6
Pertuzumab	56	16.2	16.2
Haloperidol	50	16.2	16.2
Haloperidol Lactate	50	15.9	15.9
Dicyclomine Hydrochloride	27	14.8	14.8
Fluticasone Propionate Nasal	55	14.3	14.3
Mupirocin Calcium	25	14.2	14.2
Mupirocin	24	13.8	13.9
Fluticasone Propionate	211	13.5	13.5
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	82	13.0	13.0
Piperacillin Sodium,Tazobactam Sodium	42	12.4	12.4
Aripiprazole Oral	57	10.8	10.9
Aripiprazole Orally Disintegrating	57	10.8	10.9
Cyclobenzaprine Hydrochloride	12	10.3	10.4
Azelastine	23	10.0	10.0
Ciclesonide	17	9.7	9.7
Mometasone	22	9.3	9.3
Mometasone Furoate	48	9.0	9.0
Cefuroxime	13	8.8	8.8
Triamcinolone Acetonide	33	8.3	8.3
Trastuzumab	72	8.3	8.3
Lifitegrast	17	8.1	8.1
Esomeprazole Magnesium Capsule, Delayed Release	15	8.0	8.0
Esomeprazole Magnesium Delayed Release Capsules	15	8.0	8.0
Esomeprazole Magnesium Dihydrate	15	8.0	8.0
Carboxymethylcellulose Sodium	9	7.4	7.4
Morphine	70	7.4	7.4
Duloxetine	64	7.2	7.2
Desloratadine	10	7.2	7.2
Fenofibrate	32	7.0	7.0
Levofloxacin	54	7.0	7.0
Levofloxacin In 5% Dextrose	54	7.0	7.0
Docetaxel Anhydrous	60	7.0	7.0
Docetaxel	60	7.0	7.0
Lanreotide Acetate	7	6.9	6.9
Lubiprostone	8	6.5	6.5
Sucralfate Oral	12	6.5	6.5
Sucralfate Oral Suspension	12	6.5	6.5
Irbesartan	37	6.5	6.5
Zinc Gluconate	21	6.2	6.2
Epoprostenol	10	5.9	5.9
Cabozantinib	36	5.8	5.9
Anastrozole Tablets	16	5.8	5.8
Linagliptin	13	5.5	5.5
Rizatriptan Benzoate	7	5.3	5.3
Desoximetasone	12	4.9	4.9
Paclitaxel (Aibumin-Bound)	50	4.8	4.8
Paclitaxel	51	4.0	4.0
Botulinum Toxin Type A	6	3.7	3.7
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	3.7	3.7
Bimekizumab	10	3.6	3.6
Fexofenadine Hydrochloride	10	3.6	3.6
Clozapine	57	3.6	3.6
Risperidone	60	3.5	3.5
Abemaciclib	8	3.1	3.1
Riociguat	13	3.1	3.1
Esketamine Hydrochloride	7	3.0	3.0
Sarilumab	10	2.9	2.9
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	15	2.8	2.8
Axitinib	7	2.8	2.8
Denosumab	70	2.7	2.7
Belimumab	11	2.7	2.7
Alpelisib	3	2.7	2.7
Ranitidine	61	2.4	2.4
Palbociclib	28	2.3	2.3
Pseudoephedrine Hcl	3	2.1	2.1
Onabotulinumtoxina	19	1.9	1.9
Nirmatrelvir And Ritonavir	13	1.9	1.9
Dupilumab	111	1.8	1.8
Osimertinib	7	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.